Insider Selling: Spark Therapeutics, Inc. (ONCE) Insider Sells $255,060.00 in Stock
Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Daniel Faga sold 3,000 shares of Spark Therapeutics stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.02, for a total value of $255,060.00. Following the sale, the insider now owns 3,000 shares in the company, valued at $255,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Daniel Faga also recently made the following trade(s):
- On Monday, July 24th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $70.00, for a total value of $210,000.00.
- On Thursday, June 29th, Daniel Faga sold 4,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $62.71, for a total value of $282,195.00.
Spark Therapeutics, Inc. (NASDAQ:ONCE) opened at 81.71 on Thursday. Spark Therapeutics, Inc. has a 1-year low of $35.07 and a 1-year high of $85.26. The stock has a 50 day moving average price of $82.71 and a 200 day moving average price of $69.14. The stock’s market cap is $2.55 billion.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.75) by ($0.14). The company had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The firm’s revenue was up 14.7% compared to the same quarter last year. During the same period last year, the business posted ($1.04) EPS. On average, analysts predict that Spark Therapeutics, Inc. will post ($7.69) EPS for the current fiscal year.
Several research firms have commented on ONCE. Jefferies Group LLC began coverage on Spark Therapeutics in a report on Monday, July 10th. They issued a “buy” rating and a $85.00 target price on the stock. Cantor Fitzgerald set a $94.00 target price on Spark Therapeutics and gave the stock a “buy” rating in a report on Monday, July 17th. ValuEngine downgraded Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 20th. BidaskClub raised Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Finally, Zacks Investment Research raised Spark Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 19th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $83.77.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Ameritas Investment Partners Inc. boosted its position in Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 389 shares in the last quarter. Cubist Systematic Strategies LLC bought a new stake in Spark Therapeutics during the 2nd quarter valued at $143,000. BNP Paribas Arbitrage SA boosted its position in Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,449 shares in the last quarter. Pacad Investment Ltd. boosted its position in Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Highbridge Capital Management LLC bought a new stake in Spark Therapeutics during the 1st quarter valued at $227,000. 91.01% of the stock is currently owned by institutional investors and hedge funds.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Stock Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related stocks with our FREE daily email newsletter.